Investigational drug · Phase 3
SGM-101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Colorectal Neoplasms.
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 24, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
8
Any phase or sponsor naming "SGM-101"
First trial start
2019
Jun 17, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SGM-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Colorectal Neoplasms
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "SGM-101" as an intervention, largest first.
- Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal CancerPivotal-lookingRecruiting
SurgimabIndustry
NCT03659448 · 300 participants (planned) · Start Jun 17, 2019 · Primary completion Nov 2024
Drug: SGM-101 · For: Colorectal Neoplasms
Sites: Duarte, California; La Jolla, California; Weston, Florida · 11 sites in all
- SGM-101 in Locally Advanced and Recurrent Rectal CancerPivotal-lookingStatus unknown
Leiden University Medical CenterAcademic, hospital or other
NCT04642924 · 203 participants (planned) · Start Oct 22, 2019 · Primary completion Oct 2021
Drug: SGM-101 · For: Rectal Cancer; Recurrent Rectal Cancer
Sites: Amsterdam, Netherlands; Eindhoven, Netherlands; Rotterdam, Netherlands · 4 sites in all
SurgimabIndustry
NCT02973672 · 75 participants · Start Jan 2016 · Primary completion Apr 15, 2019
Drug: SGM-101 · For: Colon Cancer; Rectum Cancer; Pancreas Cancer and 2 more
Sites: Eindhoven, Netherlands; Leiden, Netherlands; Rotterdam, Netherlands
- SGM-101 Tumor Targeted Fluorescence Endoscopy in Rectal Polyps With Suspected T1 Adenocarcinoma or High Grade DysplasiaStatus unknown
Leiden University Medical CenterAcademic, hospital or other
NCT06280690 · 20 participants (planned) · Start Jan 31, 2024 · Primary completion Apr 30, 2025
Drug: SGM-101 · For: Colorectal Cancer; Image; Low Grade Dysplasia of Colon
Sites: Leiden, Netherlands
- SGM-101 in Colorectal Lung MetastasesStatus unknown
Leiden University Medical CenterAcademic, hospital or other
NCT04737213 · 10 participants (planned) · Start Nov 1, 2020 · Primary completion Nov 1, 2021
Drug: SGM-101 · For: Colorectal Cancer; Metastatic Colon Cancer
Sites: Leiden, Netherlands; Rotterdam, Netherlands
Sunil SinghalAcademic, hospital or other
NCT04315467 · 10 participants · Start Jul 8, 2020 · Primary completion Feb 10, 2022
Drug: SGM-101 · For: Lung Cancer; Lung Nodule; Non Small Cell Lung Cancer
Sites: Philadelphia, Pennsylvania
- SGM-101 in Colorectal Brain Metastases.Status unknown
Leiden University Medical CenterAcademic, hospital or other
NCT04755920 · 10 participants (planned) · Start Jan 1, 2024 · Primary completion Feb 2026
Drug: SGM-101 · For: Rectal Neoplasms; Rectum Cancer; Colorectal Neoplasms and 10 more
Sites: Leiden, Netherlands; The Hague, Netherlands
- Fluorescence-guided Resection Of Colorectal Liver Metastases Using SGM-101 and Indocyanine GREENStatus unknown
Leiden University Medical CenterAcademic, hospital or other
NCT05965817 · 10 participants (planned) · Start Dec 1, 2023 · Primary completion Mar 1, 2025
Drug: SGM-101 op top of ICG · For: Colorectal Cancer; Liver Metastasis Colon Cancer; Image
Sites: Leiden, Netherlands
Newest research
PubMed records naming it or its code names, newest first.
- Variation in SGM-101 fluorescence is associated with tumor biology in primary colorectal cancer and colorectal liver metastases.
Matoshi A, Warmerdam MI, Keizer MJ, et al. · Surg Oncol 2026
- CEA-targeted fluorescence endoscopy for the detection of high-grade dysplasia and early invasive rectal cancer: A proof-of-concept trial.
Warmerdam MI, Dijkhuis TH, Linders DJG, et al. · Eur J Nucl Med Mol Imaging 2026
- Fluorescent Anti-CEA Antibody Detects Submillimeter Colon Cancer Metastases.
Bravo J, Liu S, Jaiswal S, et al. · J Surg Res 2026
- Tumour-targeted fluorescence-guided surgery in gastrointestinal cancer: A systematic review of preclinical and clinical research.
Darai A, Graus EHM, van der Stroom FJA, et al. · Clin Transl Med 2026
- Feasibility of Anti-CEA Dye Conjugate for Cancer-Specific Imaging in Gastric Cancer Cell Lines and Mouse Xenograft Models.
Jeong K, Koo AE, Yoo J, et al. · Cancers (Basel) 2025
- Long-term Local Control Following CEA-targeted Fluorescence-guided Surgery in Patients With Locally Advanced and Recurrent Rectal Cancer.
Warmerdam MI, Creemers DMJ, Kusters M, et al. · Mol Imaging Biol 2025
Also in development for Colorectal Neoplasms
- OlomorasibLY3537982Phase 36 trials
Eli Lilly · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Neoplasm Metastasis
- FluoropyrimidinePhase 33 trials
Seattle Project Corporation · Colorectal Neoplasms, Gastric or Gastroesophageal Junction Adenocarcinoma, Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
- BLU-924SAR449336Phase 21 trial
Blueprint Medicines Corporation · Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms
- DM002Phase 21 trial
Xadcera Biopharmaceutical (Suzhou) Co., Ltd. · Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms
- E7386Phase 21 trial
Eisai · Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.